Thus, the redox microenvironment may modulate the monomer/dimer equilibrium of gremlin during tumor growth, resulting in either a pro- or anti-angiogenic phenotype because of the balance between the VEGFR2 agonist and antagonist activity of the protein. This evidence concerns the gene GREM1 and neoplasm.